The Global Vascular Closure Devices (VCD) Market is entering a transformative period in 2026, characterized by a transition from traditional manual compression to high-precision, biodegradable, and automated closure systems. As interventional procedures move increasingly into Ambulatory Surgical Centers (ASCs), the demand for "immediate hemostasis" has become the primary clinical driver, allowing for same-day discharge and significantly improved patient throughput.
Market Valuation & Forecast (2025–2036)
The Global Vascular Closure Devices Market was valued at approximately USD 1.82 Billion in 2025. It is projected to reach USD 3.24 Billion by the year 2036, growing at a steady CAGR of 5.4% globally.
Segments Analysis
The market is evolving beyond simple approximators into specialized material-based solutions.
| Category | Key Segments |
| By Type | Active Approximators (Suture-mediated, Clip-based, Mechanical), Passive Approximators (Collagen plugs, Sealant/Gel-based), External Hemostatic Devices. |
| By Access Route | Femoral Access (Dominant), Radial Access (Fastest growing due to lower complication rates). |
| By Hole Size | Small-Bore VCDs (Standard diagnostic), Large-Bore VCDs (Essential for TAVR/EVAR procedures). |
| By Material | Bioresorbable Polymers, Collagen-Based, Nitinol-Clip Systems, Synthetic Sealants. |
| By End-User | Hospitals, Ambulatory Surgical Centers (ASCs), Specialized Cardiac Centers. |
Regional Analysis
-
North America: The market leader (~44%). Growth is sustained by a high volume of Percutaneous Coronary Interventions (PCI) and the rapid expansion of structural heart programs requiring large-bore closure solutions.
-
Europe: A mature market with a high preference for Radial Access and suture-mediated devices. The implementation of EU MDR regulations in 2025–2026 is consolidating the market toward larger, compliant players.
-
Asia-Pacific: The highest growth potential (7.8% CAGR). Driven by infrastructure investments in China and India, where a burgeoning middle class is gaining access to advanced interventional cardiology.
-
LAMEA: Increasing adoption in private healthcare sectors in Brazil and the GCC, where reducing hospital stays is a key economic priority.
Top Key Players
-
Global Tier-1: Abbott Laboratories (Perclose/StarClose), Terumo Corporation (Angio-Seal), Teleflex (Cordis), Medtronic.
-
Specialized Innovators: Haemonetics (VASCADE), Cardiva Medical, Vivasure Medical (PerQseal), Vasorum Ltd. (Celt ACD).
-
Emerging & Regional: Merit Medical Systems, Inseal Medical, Tricol Biomedical, TZ Medical, B. Braun.
Porter’s Five Forces
-
Bargaining Power of Buyers (High): Hospital GPOs (Group Purchasing Organizations) exert intense pressure on pricing, often bundling VCDs with wider interventional cardiology portfolios.
-
Threat of New Entrants (Low): High regulatory hurdles (FDA/CE Mark) and the need for extensive clinical trial data for bio-absorbable materials prevent rapid entry.
-
Bargaining Power of Suppliers (Moderate): Suppliers of medical-grade collagen and specialized nitinol have leverage, as material purity is critical for preventing foreign-body reactions.
-
Threat of Substitutes (Moderate): Manual compression and radial compression bands are low-cost alternatives, but they cannot compete with VCDs on patient ambulation speed.
-
Competitive Rivalry (High): Major players compete fiercely on "Ease-of-Use" and clinical complication rates (hematoma/infection).
SWOT Analysis
-
Strengths: Rapid ambulation (patients walk sooner); high clinical success rates (>97%); significant reduction in nursing staff monitoring time.
-
Weaknesses: High cost per unit compared to manual compression; steep learning curve for large-bore devices.
-
Opportunities: Bio-reabsorbable technology that leaves no permanent implant; expansion into Neurovascular and Peripheral closure applications.
-
Threats: Product recalls due to infection risks; shifts toward transradial access which uses cheaper compression bands.
Trend Analysis 2026
-
The Large-Bore Surge: With the rise of TAVR (Transcatheter Aortic Valve Replacement), there is a critical need for devices that can close 14F to 24F arterial punctures without surgical intervention.
-
AI-Guided Deployment: Integration of ultrasound-guided feedback within the closure device handle to ensure perfect placement against the arterial wall.
-
Sutureless "Plug & Forget": Increasing preference for hydrogel and collagen plugs that dissolve completely within 60–90 days, leaving the vessel natural for future re-access.
Drivers & Challenges
-
Driver: The "Graying" Population: Increasing incidence of CVD in the elderly necessitates minimally invasive procedures where VCDs reduce the risk of post-op bleeding.
-
Driver: Economic Efficiency: VCDs save an average of USD 200–$350 per procedure by reducing the length of hospital stay and bed-occupancy time.
-
Challenge: Complication Management: Though rare, complications like pseudoaneurysms or arterial stenosis require surgical repair, acting as a deterrent for some conservative clinicians.
-
Challenge: Regulatory Compliance: The cost of maintaining clinical evidence under new global regulatory frameworks (like EU MDR) is increasing R&D overheads.
Value Chain Analysis
-
Biomaterial Engineering: Development of hemostatic agents (collagen/fibrin) and absorbable polymers.
-
Precision Manufacturing: Micro-machining of nitinol clips and complex delivery catheters.
-
Clinical Validation: Multi-center trials to prove safety across diverse patient anatomies (e.g., obese or calcified vessels).
-
Strategic Distribution: Direct-to-hospital sales models paired with intensive "in-service" training for cath lab staff.
Quick Recommendations for Stakeholders
-
For Manufacturers: Focus on Re-access Friendly designs. Interventionalists are often hesitant to use clips if they believe they will need to puncture the same site in the future.
-
For ASC Administrators: Invest in Total Closure Solutions. Transitioning to VCDs can increase your daily case capacity by 20% due to faster patient turnaround.
-
For Investors: Target companies with Large-Bore (12F+) expertise. As structural heart procedures become the norm, the "big hole" closure market will command the highest margins.
1. Market Overview of Vascular Closure Devices
1.1 Vascular Closure Devices Market Overview
1.1.1 Vascular Closure Devices Product Scope
1.1.2 Market Status and Outlook
1.2 Vascular Closure Devices Market Size by Regions:
1.3 Vascular Closure Devices Historic Market Size by Regions
1.4 Vascular Closure Devices Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Vascular Closure Devices Sales Market by Type
2.1 Global Vascular Closure Devices Historic Market Size by Type
2.2 Global Vascular Closure Devices Forecasted Market Size by Type
2.3 Passive Approximators
2.4 Active Approximators
3. Covid-19 Impact Vascular Closure Devices Sales Market by Application
3.1 Global Vascular Closure Devices Historic Market Size by Application
3.2 Global Vascular Closure Devices Forecasted Market Size by Application
3.3 Interventional Cardiology
3.4 Interventional Radiology/Vascular Surgery
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Vascular Closure Devices Production Capacity Market Share by Manufacturers
4.2 Global Vascular Closure Devices Revenue Market Share by Manufacturers
4.3 Global Vascular Closure Devices Average Price by Manufacturers
5. Company Profiles and Key Figures in Vascular Closure Devices Business
5.1 Terumo Corporation
5.1.1 Terumo Corporation Company Profile
5.1.2 Terumo Corporation Vascular Closure Devices Product Specification
5.1.3 Terumo Corporation Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.2 Abbott Laboratories
5.2.1 Abbott Laboratories Company Profile
5.2.2 Abbott Laboratories Vascular Closure Devices Product Specification
5.2.3 Abbott Laboratories Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.3 Cardinal Health Inc. (Cordis)
5.3.1 Cardinal Health Inc. (Cordis) Company Profile
5.3.2 Cardinal Health Inc. (Cordis) Vascular Closure Devices Product Specification
5.3.3 Cardinal Health Inc. (Cordis) Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.4 Cardiva Medical Inc.
5.4.1 Cardiva Medical Inc. Company Profile
5.4.2 Cardiva Medical Inc. Vascular Closure Devices Product Specification
5.4.3 Cardiva Medical Inc. Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.5 Medtronic
5.5.1 Medtronic Company Profile
5.5.2 Medtronic Vascular Closure Devices Product Specification
5.5.3 Medtronic Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.6 Morris Innovative Inc.
5.6.1 Morris Innovative Inc. Company Profile
5.6.2 Morris Innovative Inc. Vascular Closure Devices Product Specification
5.6.3 Morris Innovative Inc. Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.7 Essential Medical Inc.
5.7.1 Essential Medical Inc. Company Profile
5.7.2 Essential Medical Inc. Vascular Closure Devices Product Specification
5.7.3 Essential Medical Inc. Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.8 Merit Medical Systems Inc.
5.8.1 Merit Medical Systems Inc. Company Profile
5.8.2 Merit Medical Systems Inc. Vascular Closure Devices Product Specification
5.8.3 Merit Medical Systems Inc. Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.9 Vasorum Ltd.
5.9.1 Vasorum Ltd. Company Profile
5.9.2 Vasorum Ltd. Vascular Closure Devices Product Specification
5.9.3 Vasorum Ltd. Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.10 TZ Medical Inc.
5.10.1 TZ Medical Inc. Company Profile
5.10.2 TZ Medical Inc. Vascular Closure Devices Product Specification
5.10.3 TZ Medical Inc. Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.11 Vivasure Medical Ltd.
5.11.1 Vivasure Medical Ltd. Company Profile
5.11.2 Vivasure Medical Ltd. Vascular Closure Devices Product Specification
5.11.3 Vivasure Medical Ltd. Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.12 Inseal Medical Ltd.
5.12.1 Inseal Medical Ltd. Company Profile
5.12.2 Inseal Medical Ltd. Vascular Closure Devices Product Specification
5.12.3 Inseal Medical Ltd. Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
5.13 Tricol Biomedical Inc
5.13.1 Tricol Biomedical Inc Company Profile
5.13.2 Tricol Biomedical Inc Vascular Closure Devices Product Specification
5.13.3 Tricol Biomedical Inc Vascular Closure Devices Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Vascular Closure Devices Market Size
6.2 North America Vascular Closure Devices Key Players in North America
6.3 North America Vascular Closure Devices Market Size by Type
6.4 North America Vascular Closure Devices Market Size by Application
7. East Asia
7.1 East Asia Vascular Closure Devices Market Size
7.2 East Asia Vascular Closure Devices Key Players in North America
7.3 East Asia Vascular Closure Devices Market Size by Type
7.4 East Asia Vascular Closure Devices Market Size by Application
8. Europe
8.1 Europe Vascular Closure Devices Market Size
8.2 Europe Vascular Closure Devices Key Players in North America
8.3 Europe Vascular Closure Devices Market Size by Type
8.4 Europe Vascular Closure Devices Market Size by Application
9. South Asia
9.1 South Asia Vascular Closure Devices Market Size
9.2 South Asia Vascular Closure Devices Key Players in North America
9.3 South Asia Vascular Closure Devices Market Size by Type
9.4 South Asia Vascular Closure Devices Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Vascular Closure Devices Market Size
10.2 Southeast Asia Vascular Closure Devices Key Players in North America
10.3 Southeast Asia Vascular Closure Devices Market Size by Type
10.4 Southeast Asia Vascular Closure Devices Market Size by Application
11. Middle East
11.1 Middle East Vascular Closure Devices Market Size
11.2 Middle East Vascular Closure Devices Key Players in North America
11.3 Middle East Vascular Closure Devices Market Size by Type
11.4 Middle East Vascular Closure Devices Market Size by Application
12. Africa
12.1 Africa Vascular Closure Devices Market Size
12.2 Africa Vascular Closure Devices Key Players in North America
12.3 Africa Vascular Closure Devices Market Size by Type
12.4 Africa Vascular Closure Devices Market Size by Application
13. Oceania
13.1 Oceania Vascular Closure Devices Market Size
13.2 Oceania Vascular Closure Devices Key Players in North America
13.3 Oceania Vascular Closure Devices Market Size by Type
13.4 Oceania Vascular Closure Devices Market Size by Application
14. South America
14.1 South America Vascular Closure Devices Market Size
14.2 South America Vascular Closure Devices Key Players in North America
14.3 South America Vascular Closure Devices Market Size by Type
14.4 South America Vascular Closure Devices Market Size by Application
15. Rest of the World
15.1 Rest of the World Vascular Closure Devices Market Size
15.2 Rest of the World Vascular Closure Devices Key Players in North America
15.3 Rest of the World Vascular Closure Devices Market Size by Type
15.4 Rest of the World Vascular Closure Devices Market Size by Application
16 Vascular Closure Devices Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Segments Analysis
The market is evolving beyond simple approximators into specialized material-based solutions.
| Category | Key Segments |
| By Type | Active Approximators (Suture-mediated, Clip-based, Mechanical), Passive Approximators (Collagen plugs, Sealant/Gel-based), External Hemostatic Devices. |
| By Access Route | Femoral Access (Dominant), Radial Access (Fastest growing due to lower complication rates). |
| By Hole Size | Small-Bore VCDs (Standard diagnostic), Large-Bore VCDs (Essential for TAVR/EVAR procedures). |
| By Material | Bioresorbable Polymers, Collagen-Based, Nitinol-Clip Systems, Synthetic Sealants. |
| By End-User | Hospitals, Ambulatory Surgical Centers (ASCs), Specialized Cardiac Centers. |
Regional Analysis
-
North America: The market leader (~44%). Growth is sustained by a high volume of Percutaneous Coronary Interventions (PCI) and the rapid expansion of structural heart programs requiring large-bore closure solutions.
-
Europe: A mature market with a high preference for Radial Access and suture-mediated devices. The implementation of EU MDR regulations in 2025–2026 is consolidating the market toward larger, compliant players.
-
Asia-Pacific: The highest growth potential (7.8% CAGR). Driven by infrastructure investments in China and India, where a burgeoning middle class is gaining access to advanced interventional cardiology.
-
LAMEA: Increasing adoption in private healthcare sectors in Brazil and the GCC, where reducing hospital stays is a key economic priority.
Top Key Players
-
Global Tier-1: Abbott Laboratories (Perclose/StarClose), Terumo Corporation (Angio-Seal), Teleflex (Cordis), Medtronic.
-
Specialized Innovators: Haemonetics (VASCADE), Cardiva Medical, Vivasure Medical (PerQseal), Vasorum Ltd. (Celt ACD).
-
Emerging & Regional: Merit Medical Systems, Inseal Medical, Tricol Biomedical, TZ Medical, B. Braun.
